BioRock Ventures Name

PTM Therapeutics is focused on developing therapies for chronic diseases and cancer, utilizing its innovative post-translational modification technology. Founded in the San Francisco Bay Area, the company aims to identify disease-specific targets on therapeutic antibodies. This technology enables the differentiation of healthy cells from diseased ones and plays a crucial role in addressing various biological dysfunctions. By leveraging this approach, PTM Therapeutics supports pharmaceutical developers in discovering new targets and creating effective therapeutics for complex health conditions.

Veana Therapeutics, Inc. is a biotechnology company based in Portland, Oregon, focused on developing innovative cancer-fighting immunotherapeutic products. Established in 2012, the company specializes in α-TEA-based cancer immunotherapy technologies that aim to provide safe and effective treatments for various cancers. Veana Therapeutics is committed to creating oral mitochondrial inhibitors that selectively target and kill cancer cells while also stimulating the immune system. This dual action not only aims to enhance the effectiveness of cancer treatment but also strives to improve the quality of life for patients during and after their therapy.

Octagon Therapeutics, Inc. is a preclinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibiotic medicines for life-threatening autoimmune diseases such as Pemphigus Vulgaris, Systemic Lupus, and Multiple Sclerosis. Founded in 2016, the company is dedicated to addressing multi-drug resistant infections and has shown effectiveness against critical pathogens identified by the World Health Organization. Octagon's targeted immunomodulator medicines aim to restore immune balance in patients with chronic autoimmune and inflammatory conditions by selectively targeting dysregulated immune cells, thereby helping patients avoid chronic immunosuppression. The company's operations are supported by a state-of-the-art facility adjacent to Harvard University, enabling efficient development of its therapies with minimal overhead. The management team comprises experienced scientists, clinicians, and entrepreneurs, contributing to a growing pool of research talent dedicated to advancing drug development.

Celldom, Inc. is a research tools company based in Durham, North Carolina, established in 2016. It specializes in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing the diversity within cell populations. The company's flagship product, the TrapTx Analyzer System, integrates phenotypic and genomic data on a large scale, allowing for the identification and characterization of rare cells that are crucial in various biological pathways and diseases. Celldom focuses on applications in oncology, immunology, and stem cell biology, providing innovative solutions that enable researchers to automate the analysis of cellular heterogeneity effectively.

Primmune Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule, orally administered toll-like receptor 7 (TLR7) agonists for cancer immunotherapy. Founded in 2017, the company aims to stimulate innate immunity to enhance the effectiveness of adaptive cancer treatments, such as checkpoint inhibitors. Its TLR7 agonist is designed to activate the immune system by producing cytokines and chemokines that boost cellular responses and facilitate the activation of natural killer cells. This approach enables healthcare providers to target metastatic diseases more effectively and promotes B-cell proliferation and activation, ultimately improving overall response rates and treatment durability for patients.

Primmune Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule, orally administered toll-like receptor 7 (TLR7) agonists for cancer immunotherapy. Founded in 2017, the company aims to stimulate innate immunity to enhance the effectiveness of adaptive cancer treatments, such as checkpoint inhibitors. Its TLR7 agonist is designed to activate the immune system by producing cytokines and chemokines that boost cellular responses and facilitate the activation of natural killer cells. This approach enables healthcare providers to target metastatic diseases more effectively and promotes B-cell proliferation and activation, ultimately improving overall response rates and treatment durability for patients.

Seal Rock Therapeutics is a biotechnology company focused on developing small-molecule inhibitors targeting ASK1 (Apoptosis signal-regulating kinase 1), a protein involved in apoptosis, inflammation, and fibrosis. The company primarily aims to address hepatic conditions, particularly non-alcoholic steatohepatitis (NASH), which is a fatty liver disease characterized by inflammation and cellular damage leading to liver fibrosis. In addition to NASH, Seal Rock is exploring the potential of ASK1 inhibitors for treating various other conditions, including cardiac, immunological, and neurodegenerative diseases, which currently lack effective therapies.

AN2 Therapeutics, Inc. is a biopharmaceutical company based in Menlo Park, California, founded in 2017. The company is dedicated to the research, development, and commercialization of innovative medicines aimed at addressing infectious diseases. AN2 Therapeutics is focused on developing epetraborole, a once-daily oral treatment for patients suffering from chronic non-tuberculous mycobacterial lung disease, which represents a significant unmet medical need. Additionally, the company has established a strategic partnership with Brii Biosciences to enhance its development efforts.